medigraphic.com
ISSN 0188-9796 (Impreso)

2005, Número s1

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2005; 13 (s1)


Pruebas bioquímicas en neuroendocrinología

Espinosa de los Monteros SAL

Idioma: Español
Referencias bibliográficas: 32
Paginas: 7-12
Archivo PDF: 83.56 Kb.


FRAGMENTO

DIAGNÓSTICO EN EL SÍNDROME DE CUSHING

El diagnóstico del síndrome de Cushing constituye uno de los retos más grandes en endocrinología. Si bien las manifestaciones clínicas son obvias en muchos de los casos, en otros pueden ser sólo sutiles (Cushing leve).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Terzolo M, Pia A, Alin A, Osella G, Reimondo G, Bovio S et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002; 87: 998-1003.

  2. Wu T, Machacelo D, Jiang N, Hao P. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 1997; 82: 151-5.

  3. Findling J, Raff H. Diagnosis and differential diagnosis of Cushing’s syndrome. Endocrinol Metab Clin North Am 2001; 30: 729-47.

  4. Nieman L, Cutler G. The sensitivity of the urine free cortisol measurement as screening test for Cushing’s syndrome. En: Programs and abstracts of the Endocrine Society 72nd Annual Meeting, Atlanta GA 1990; pp 822.

  5. Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004; 89: 1222-6.

  6. Isidori AM, Kaltsas GA, Mohammed S et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 2003; 88: 5299-306.

  7. Word P, Barth J, Freedman D, Perry L, Sheridan B. Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome, recommendations for a protocol for biochemistry laboratories. Ann Clin Bioche 1997; 34: 222-9.

  8. Gorges R, Knappe G, Herl H. Diagnosis of Cushing’s syndrome: Re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J Endocrinol Invest 1999; 22: 241-49.

  9. Newell-Price J, Trainer P, Perry L et al. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocrinol 1995; 43: 545-50.

  10. Putignano P, Toja P, Dubini A, Giraldi F, Corsello S, Cavagnini F. Midnight salivary cortisol vs urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J Clin Endocrinol Metab 2003; 88: 4153-7.

  11. Yanovski J, Gordon C, Chrousos G, Nieman L. Corticotropin realizing hormone stimulation following low dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing states. JAMA 1993; 269: 2232-38.

  12. Papanicolaou D, Yanovski J, Cutler G, Chrousos G, Nieman L. A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing status. J Clin Endocrinol Metab 1998; 83: 1163-7.

  13. Moro M, Putignano P, Losa M, Invitti C, Maraschini C, Cavagnini F. The desmopressin test in the differential diagnosis between Cushing’s disease and pseudo-Cushing states. J Clin Endocrinol Metab 2000; 85: 3569-74.

  14. Lindsay J, Nieman L. Differential diagnosis and imaging in Cushing’s syndrome. Endocrinol Metab Clin NA 2005; 34: 403-21.

  15. Ilias I, Torpy D, Pacak N, Mullen N, Weley R, Nieman L. Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institute of Health. J Clin Endocrinol Metab 2005: 90: 4955-4962.

  16. Raff H, Findling J. A physiologic approach to diagnosis of Cushing syndrome. Ann Intern Med 2003; 138: 980-991.

  17. Flack M, Oldfiel E, Cutler G, Zweing M, Malley J, Chrousos G et al. Urine free cortisol in the high dose dexamethasone suppression test for the differential diagnosis of the Cushing’s syndrome. Ann Intern Med 1992; 116: 211-17.

  18. Tyrrel J, Findling J, Aron D, Fitzgerald P, Forsham P. An overnight high dose dexamethasone suppression test for rapid differential diagnosis of Cushing’s syndrome. Ann Intern Med 1986; 104: 180-6.

  19. Dichek H, Nieman L, Oldfield E, Pass H, Malley J, Cutler G. A comparison of the standard high dose dexamethasone suppression test for the differential diagnosis of adrenocorticotropin dependent Cushing’s syndrome. J Clin Endocrinol Metab 1994; 78: 418-22.

  20. van den Bogaert D, de Herder W, de Jong F, Biemond P, van der Lely, Lamberts S. The continuous 7-hour intravenous dexamethasone suppression test in the differential diagnosis of ACTH-dependent Cushing’s syndrome. Clin Endocrinol 1999; 51: 193-8.

  21. Nieman L, Oldfield E, Wesley R, Chrousos G, Loriaux L, Cutler G. A simplified morning ovine corticotropin releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 1993; 77: 1308-12.

  22. Bates A, Van’t Hoff W, Jones J, Clayton R. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86: 293-299.

  23. Haldaway I, Rajasoorya R, Gamble D. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89: 667-674.

  24. Ayuk J, Clayton G, Holder M, Sheppard M, Stewart P, Bates A. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89: 1613-17.

  25. Giustina A, Barkan A, Casanueva F, Cavagnini F, Forman L, Ho K et al. Criteria for use of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-29.

  26. Freda P., Nuruzzaman A, Reyes C, Sondeen R, Post K. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004; 89: 495-500.

  27. Biochemical assessment and long term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 2004; 89: 3099-3102.

  28. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3419-3426.

  29. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003; 58: 86-92.

  30. Ayuk J, Clayton G, Holder M, Sheppard M, Stewart P, Bates A. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89: 1613-17.

  31. Espinosa de los Monteros AL, Mercado M, Sosa E, Lizama O, Guinto G, López B, García O et al. Changing patterns of insulin-like growth factor–I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly. J Neurosurg 2002; 97: 287-292.

  32. Espinosa de los Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G et al. Evaluation of biochemical activity in acromegalic patients after pituitary surgery: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf). En prensa




2020     |     www.medigraphic.com